// App-Quantinova.ai

10122 : Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer.

Researchers

Presenter

  • Bernardo Leon Rapoport

Principal Investigators

  • Lee Steven Schwartzberg

  • Sujata Arora

  • Daniel Powers

  • Karin Jordan

  • Rudolph M. Navari

Medical Centers

  • The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

  • West Clinic, Memphis, TN

  • TESARO, Inc., Waltham, MA

  • Martin-Luther-University Halle-Wittenberg, Halle, Germany

  • Indiana University School of Medicine South Bend, South Bend, IN

Locations

  • United States

  • Germany

  • South Africa

Companies

  • TESARO, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chemotherapy-induced nausea and vomiting

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • NDC80 Kinetochore Complex Component

  • C-C Motif Chemokine Ligand 28

  • Serotonin

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • rolapitant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT01500226

  • NCT01499849

  • NCT01500213

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved